14,711 results match your criteria Meningococcal Meningitis


The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae.

Clin Infect Dis 2018 Dec 14. Epub 2018 Dec 14.

Institute for Glycomics, Griffith University, Gold Coast, Australia.

Background: Neisseria gonorrhoeae and Neisseria meningitidis are closely related bacteria that cause a significant global burden of disease. Control of gonorrhoea is becoming increasingly difficult due to widespread antibiotic resistance. While vaccines are routinely used for N. Read More

View Article
December 2018

Pharmacist insights into adolescent human papillomavirus vaccination provision in the United States.

Hum Vaccin Immunother 2018 Dec 14. Epub 2018 Dec 14.

a Department of Epidemiology , Gillings School of Global Public Health, University of North Carolina at Chapel Hill , Chapel Hill , NC.

HPV vaccination coverage in the United States (US) falls short of the Healthy People 2020 goal of 80% coverage among 13-15 year-old adolescents. Pharmacies are a promising alternative vaccine delivery site that may increase access to HPV vaccination. Our objective was to assess pharmacists' insights into HPV vaccination provision to adolescents. Read More

View Article
December 2018

Evaluation of Carriage with the Analysis of Serogroups, Genogroups and Clonal Complexes among Polish Soldiers.

Pol J Microbiol 2018 ;67(4):493-500

Military Institute of Medicine, Department of Epidemiology and Tropical Medicine , Warsaw , Poland.

Neisseria meningitidis is an etiological factor of invasive meningococcal disease (IMD). This Gram-negative diplococcus is transmitted from person to person via droplets or through a direct physical contact with secretions of infected patients or asymptomatic carriers. The latter account for 5-10% of the general population. Read More

View Article
January 2018

Bacteremia and meningitis caused by a novel clone of Neisseria meningitidis serogroup B.

Pediatr Int 2018 Dec 11. Epub 2018 Dec 11.

Division of Pediatrics, Uji-Tokushukai Medical Center, Uji, Japan.

View Article
December 2018

Analysis of C3 Nephritic Factors by ELISA.

Authors:
Lillemor Skattum

Methods Mol Biol 2019 ;1901:177-182

Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden.

Autoantibodies to the C3 convertase of the alternative pathway of complement, called C3 nephritic factors (C3NeF), cause persistently low C3 in the circulation and production of C3 degradation fragments due to prolonged stabilization of the C3 convertase. C3NeF are associated with glomerulopathy, acquired partial lipodystrophy, and less frequently with increased susceptibility to meningococcal infection. Analysis of C3NeF is an important part of the diagnostic workup of C3 glomerulopathy, but their identification is difficult presumably due to considerable heterogeneity. Read More

View Article
January 2019

The Meningococcal Cysteine Transport System Plays a Crucial Role in Survival in Human Brain Microvascular Endothelial Cells.

MBio 2018 Dec 11;9(6). Epub 2018 Dec 11.

RIKEN Structural Biology Laboratory, Yokohama, Japan.

While typically exists in an asymptomatic nasopharyngeal carriage state, it may cause potentially lethal diseases in humans, such as septicemia or meningitis, by invading deeper sites in the body. Since the nutrient compositions of human cells are not always conducive to meningococci, needs to exploit nutrients from host environments. In the present study, the utilization of cysteine by the meningococcal cysteine transport system (CTS) was analyzed for the pathogenesis of meningococcal infections. Read More

View Article
December 2018
4 Reads

Talk to Patients About: Meningococcal Disease.

Authors:
Sean Price

Tex Med 2018 Jul 1;114(7):46. Epub 2018 Jul 1.

Talk to Patients About: Meningococcal Disease. Read More

View Article

[Notes for the history about the Doctor Lucio Cordova Infectious Diseases Hospital].

Authors:
Laval R Enrique

Rev Chilena Infectol 2018 ;35(3):314-316

Facultad de Medicina, Pontificia Universidad Católica de Chile, Chile.

The author presents a historical review about the creation of Doctor Lucio Cordova Infectious Diseases Hospital. Lucio Cordova MD, Counselor of the Charity Board in 1938, promoted a model pavilion for the hospitalization of patients with communicable diseases. An outbreak of meningococcal meningitis, between 1941 and 1942, hurried the construction of the Infectious Disease Pavilion, which was finished in 1949. Read More

View Article
January 2018

Assessment of vaccination coverage of adolescents aged 16-18 years with an innovative electronic immunization record system.

Med Mal Infect 2018 Dec 4. Epub 2018 Dec 4.

Groupe d'études en préventologie (GEP), hôpital d'instruction des armées Robert-Picqué, 351, route de Toulouse, 33140 Villenave-d'Ornon, France.

Objectives: To measure vaccine coverage among adolescents aged 16-18 years who participated in the National Defense Preparation Day in the Aquitaine region using the free electronic immunization record.

Patients And Methods: We considered adolescents aged 16-18 years who participated in the National Defense Preparation Day in the Aquitaine region from April to October 2013. All participants received a letter explaining how to create an electronic immunization record. Read More

View Article
December 2018

Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.

Hum Vaccin Immunother 2018 Dec 10. Epub 2018 Dec 10.

e US Medical Affairs, Pfizer Inc , Cambridge , MA.

Serogroup B (MenB) is the leading cause of meningococcal disease among 16- to 23-year-olds in the United States and has been responsible for all 10 college outbreaks between 2011 and 2017. Outbreak-associated costs levy a substantial and unforeseen burden on colleges/universities and surrounding communities, in part because they involve collaboration with local and state health departments to develop points-of-dispensing (PODs) outbreak response plans and rapid mass vaccination of a large at-risk student population. The MenB outbreak at Providence College in 2015 was used as a case study to develop an Excel-based Meningococcal Outbreak Cost Calculator that uses target populations for mass vaccination to estimate the costs and resources associated with a meningococcal disease outbreak response. Read More

View Article
December 2018

A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.

mSphere 2018 Dec 5;3(6). Epub 2018 Dec 5.

Vaccine Clinical Research and Development, Pfizer Inc., Pearl River, New York, USA.

carriage data are necessary to inform serogroup B (NmB) immunization program implementation. This longitudinal study compared detection methods to measure throat carriage prevalence in Quebec from November 2010 to December 2013 using cultured swab isolates and direct swab PCR from students in ninth grade (aged 13 to 15 years; = 534) and eleventh grade/college entry (16 to 18 years; = 363) and in university students in dormitories (18 to 25 years; = 360) at 3 time points per group. Meningococcal and NmB carriage rates were lower in ninth- and eleventh-grade/college entry students than university students, regardless of methodology. Read More

View Article
December 2018

Meningococcal meningitis presenting postinfant group B meningococcal immunisation.

Arch Dis Child 2018 Dec 5. Epub 2018 Dec 5.

Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.

View Article
December 2018
1 Read

Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors:

Lancet Neurol 2018 Dec 13;17(12):1061-1082. Epub 2018 Nov 13.

Background: Acute meningitis has a high case-fatality rate and survivors can have severe lifelong disability. We aimed to provide a comprehensive assessment of the levels and trends of global meningitis burden that could help to guide introduction, continuation, and ongoing development of vaccines and treatment programmes.

Methods: The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2016 study estimated meningitis burden due to one of four types of cause: pneumococcal, meningococcal, Haemophilus influenzae type b, and a residual category of other causes. Read More

View Article
December 2018
1 Read

A cross-sectional study to assess the awareness and practices related to adult immunization among nursing students in a metropolitan city.

J Educ Health Promot 2018 29;7:129. Epub 2018 Oct 29.

Department of Community Medicine, Seth G. S. Medical College and KEM Hospital, Mumbai, Maharashtra, India.

Introduction: Immunization against vaccine-preventable diseases in adults is the need of the hour. The student nurses by virtue of training are the frontline health workers dealing with patient care. They are exposed to maximum risk of contracting the diseases. Read More

View Article
October 2018
4 Reads

A qualitative exploration of facilitators and barriers to meningitis vaccination uptake among men who have sex with men.

Prev Med Rep 2019 Mar 1;13:41-47. Epub 2018 Nov 1.

Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.

Invasive Meningococcal Disease is a deadly, but preventable disease, with community outbreaks occurring at rate of 9.5 per year. Serogroup C Invasive Meningococcal Disease (IMD) community outbreaks in men who have sex with men (MSM) have been reported with greater frequency in large urban areas since 2010. Read More

View Article
March 2019
1 Read

Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy.

Medicina (Kaunas) 2018 Dec 3;54(6). Epub 2018 Dec 3.

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 5, Via Luciano Armanni, 80138 Naples, Italy.

Vaccination against bacterial pathogens is decisive for preventing invasive meningococcal disease and pediatricians play a pivotal role in vaccination compliance and coverage. The aim of this study was to investigate awareness, attitude, and practices toward the vaccine against Meningococcal B serogroup (4CMenB) among a sample of Italian pediatricians. A cross-sectional study was carried out using an online questionnaire from March to May 2015. Read More

View Article
December 2018
1 Read

B Part of It study: a longitudinal study to assess carriage of Neisseria meningitidis in first year university students in South Australia.

Hum Vaccin Immunother 2018 Dec 4. Epub 2018 Dec 4.

a Vaccinology and Immunology Research Trials Unit , Women's and Children's Health Network , Adelaide , SA , Australia.

Objectives: N. meningitidis carriage in Australia is poorly understood. This study aimed to estimate prevalence and risk factors for carriage of N. Read More

View Article
December 2018
2 Reads

Attitudes of physicians concerning vaccines not included in the national immunization schedule.

Turk J Pediatr 2018 ;60(3):290-297

Departments of Social Pediatrics, Gazi University Faculty of Medicine, Ankara, Turkey.

Çataklı T, Duyan-Çamurdan A, Aksakal-Baran FN, Güven AE, Beyazova U. Attitudes of physicians concerning vaccines not included in the national immunization schedule. Turk J Pediatr 2018; 60: 290-297. Read More

View Article
January 2018
2 Reads

The role of gonococcal Neisserial surface protein A (NspA) in serum resistance and comparison of its factor H binding properties with that of its meningococcal counterpart.

Infect Immun 2018 Dec 3. Epub 2018 Dec 3.

Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605.

the causative agent of gonorrhea, has evolved several mechanisms to subvert complement, including binding of the complement inhibitor factor H (FH). We previously reported FH binding to independently of lipooligosaccharide (LOS) sialylation. Here we report that Factor H-like protein 1 (FHL-1), which contains FH domains 1 through 7 and possesses complement inhibitory activity, also binds to The ligand for both FH and FHL-1 was identified as Neisserial surface protein A (NspA), which has previously been identified as a ligand for these molecules on As with -NspA, NspA bound FH/FHL-1 through FH domains 6 and 7. Read More

View Article
December 2018
1 Read
3.731 Impact Factor

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom.

Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with lactate dehydrogenase (LDH) ≥1. Read More

View Article
December 2018
1 Read

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Transplantation (BMT) Unit, Saint-Louis Hospital and University Paris Diderot Paris, France.

Ravulizumab, a new complement C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH). This study assessed noninferiority of ravulizumab to eculizumab in clinically stable PNH patients during previous eculizumab therapy. In this phase 3, open-label, multicenter study, 195 PNH patients on labeled-dose (900 mg every 2 weeks) eculizumab for greater than 6 months were randomly assigned 1:1 to switch to ravulizumab (n = 97) or continue eculizumab (n = 98). Read More

View Article
December 2018
1 Read

Subdural effusion and ischemic stroke complicating meningococcal meningitis in an adult.

J Microbiol Immunol Infect 2018 Nov 22. Epub 2018 Nov 22.

Department of Infectious Disease, Buddhist Tzu Chi General Hospital, Hualien, Taiwan. Electronic address:

View Article
November 2018
1 Read
2.349 Impact Factor

Vaccine-preventable disease control in the People's Republic of China: 1949-2016.

Vaccine 2018 Dec 26;36(52):8131-8137. Epub 2018 Nov 26.

National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China. Electronic address:

Background: China's immunization program is one of the oldest and largest in the world. Rates of vaccine-preventable diseases (VPD) are comparable to those in high-income countries. The program's evolution has been characterized by ambitious target setting and innovative strategies that have not been widely described. Read More

View Article
December 2018
2 Reads

Managing the risk of bacterial meningitis among healthcare workers.

Occup Med (Lond) 2018 Nov 29. Epub 2018 Nov 29.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Background: Meningococcal disease is generally caused by A, B, C, W and Y subgroups of Neisseria meningitidis. In 2015, the Italian mass media focused on this disease due to the death of two nurses. This generated alarm in the general population, especially in healthcare workers (HCWs). Read More

View Article
November 2018
6 Reads

A comparison of pyrogen detection tests in the quality control of meningococcal conjugate vaccines: The applicability of the Monocyte Activation Test.

Altern Lab Anim 2018 Nov;46(5):255-272

Departamento de Controle de Qualidade, Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

The meningococcal C conjugate vaccine (MenCC) is an interesting model with which to test the efficacy of the Monocyte Activation Test (MAT) as an alternative method of pyrogen testing in the quality control of vaccines. The MenCC that has been produced by Bio-Manguinhos in Brazil is in the final development stage, and, as recommended in the guidelines for MenCC production, its pyrogen content must be determined by using the Limulus Amoebocyte Lysate (LAL) assay and the Rabbit Pyrogen Test (RPT). This represents an ideal opportunity to compare LAL and RPT data with data obtained by using a MAT system with cryopreserved whole blood and IL-6/IL-1β as marker readouts. Read More

View Article
November 2018
1 Read

Fever after meningococcal B immunisation: A case series.

J Paediatr Child Health 2018 Nov 28. Epub 2018 Nov 28.

Emergency Department, Royal Hospital for Children, Glasgow, United Kingdom.

Aim: To document the clinical features and management of infants presenting with fever after their first meningococcal B vaccination and develop guidance for clinicians.

Methods: A prospective case series over 12 months was conducted in a tertiary paediatric hospital. Infants ≤3 months of age with fever who had received their first set of immunisations within the preceding 72 h were included. Read More

View Article
November 2018
2 Reads

Tracking a serial killer: Integrating phylogenetic relationships, epidemiology, and geography for two invasive meningococcal disease outbreaks.

PLoS One 2018 28;13(11):e0202615. Epub 2018 Nov 28.

Bureau of Communicable Disease, Department of Health and Mental Hygiene, New York, NY, United States of America.

Background: While overall rates of meningococcal disease have been declining in the United States for the past several decades, New York City (NYC) has experienced two serogroup C meningococcal disease outbreaks in 2005-2006 and in 2010-2013. The outbreaks were centered within drug use and sexual networks, were difficult to control, and required vaccine campaigns.

Methods: Whole Genome Sequencing (WGS) was used to analyze preserved meningococcal isolates collected before and during the two outbreaks. Read More

View Article
November 2018

Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?

Clin Infect Dis 2018 Jul 26. Epub 2018 Jul 26.

EHESP French School of Public Health, Sorbonne Paris Cité, France et Institut Pasteur, Paris.

Background: In Burkina Faso, serogroup A meningococcal (NmA) conjugate vaccine (PsA-TT, MenAfriVac) was introduced through a mass campaign in children and adults in December 2010. Similar to a serological survey in 2011, we followed population-level antibody persistence for 5 years after the campaign and estimated time of return to previously-published pre-vaccination levels.

Methods: We conducted 2 cross-sectional surveys in 2013 and early 2016, including representative samples (N = 600) of the general population of Bobo-Dioulasso, Burkina Faso. Read More

View Article
July 2018
3 Reads

A case report of serotype W135 epiglottitis in the United States and review of twelve adult cases of meningococcal epiglottitis.

IDCases 2018 13;14:e00466. Epub 2018 Nov 13.

Department of Pharmacy, UCHealth Medical Center of the Rockies, Loveland, CO, USA.

View Article
November 2018

Emergence and spread of resistant N. meningitidis implicated in invasive meningococcal diseases during the past decade (2008-2017).

J Antibiot (Tokyo) 2018 Nov 27. Epub 2018 Nov 27.

Laboratory of Bacteriology and Parasitology, Institut Pasteur du Maroc, Casablanca, Morocco.

Neisseria meningitidis is one of the most crucial causes of bacterial meningitis worldwide. The incidence of meningitis due to N. meningitidis greatly changes from one geographical area to the other: 500,000-1,200,000 invasive meningococcal diseases occur each year, with 50,000-135,000 deaths. Read More

View Article
November 2018
5 Reads

Vaccine preventable invasive bacterial diseases in Italy: A comparison between the national surveillance system and recorded hospitalizations, 2007-2016.

Vaccine 2019 Jan 23;37(1):41-48. Epub 2018 Nov 23.

Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), Rome, Italy. Electronic address:

Background: Vaccine-preventable invasive bacterial diseases (IBDs) caused by Neisseria meningitidis (Nm), Streptococcus pneumoniae (Sp), and Haemophilus influenzae (Hi) have been notified in Italy since 2007 without assessing reporting completeness.

Methods: Our study compared the number of cases of IBDs identified from the Italian Hospital Discharge Records (HDRs), using specific diagnostic ICD-9-CM codes, with those notified to the National Surveillance System (NSS) from 2007 to 2016. A multinomial logistic regression model was used to impute the aetiology of all discharges with a diagnosis of unspecified bacterial meningitis. Read More

View Article
January 2019
1 Read

Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis.

J Infect 2018 Nov 23. Epub 2018 Nov 23.

Public Health England, Immunisation and Countermeasures Division, 61 Colindale Avenue, London NW9 5EQ, UK. Electronic address:

View Article
November 2018
1 Read

Differential influences of complement on neutrophil responses to Neisseria meningitidis infection.

Pathog Dis 2018 Nov 1;76(8). Epub 2018 Nov 1.

Institute for Hygiene and Microbiology, University of Würzburg, 97080 Würzburg, Germany.

The complement system is the primary innate immune determinant protecting against invasive diseases caused by the Gram-negative bacterium Neisseria meningitidis (Nme, meningococcus), as evidenced by the extreme susceptibility of individuals with complement deficiencies. In contrast, the role of phagocytes such as neutrophils is much less well understood, although they are recruited in great numbers to the cerebrospinal fluid during meningococcal meningitis. Here, we consider the interaction of Nme with primary human neutrophils using either purified cells or a whole blood model of infection. Read More

View Article
November 2018
3 Reads

Neisseria meningitidis Isolated in Vitreous Humor in a 5-Month-Old Infant Death From Meningococcal Sepsis.

Am J Forensic Med Pathol 2018 Nov 20. Epub 2018 Nov 20.

Forensic Pathology and.

Diagnosing sepsis at postmortem is challenging. With respect to meningococcal sepsis, the postmortem microbiological identification of Neisseria meningitidis is nearly always due to true infection, including in cases of decomposition. Previous case series and case reports were able to isolate N. Read More

View Article
November 2018
1 Read

Invasive Meningococcal Disease in the Vaccine Era.

Front Pediatr 2018 9;6:321. Epub 2018 Nov 9.

Paediatrics, St Mary's Hospital, London, United Kingdom.

Infection with the meningococcus is one of the main causes of meningitis and septicaemia worldwide. Humans are the only natural reservoir for the meningococcus which is found primarily as a commensal inhabitant in the nasopharynx in ~10% of adults, and may be found in over 25% of individuals during adolescence. Prompt recognition of meningococcal infection and early aggressive treatment are essential in order to reduce mortality, which occurs in up to 10% of those with invasive meningococcal disease (IMD). Read More

View Article
November 2018
10 Reads

Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.

Vaccine 2018 Dec 22;36(52):8019-8027. Epub 2018 Nov 22.

Sanofi Pasteur MSD, 162 Avenue Jean Jaures, 69367 Lyon Cedex 07, France. Electronic address:

Invasive meningococcal disease caused by Neisseria meningitidis is a life-threatening disease. Several countries now include meningococcal serogroup C (MenC) conjugate and, more recently, a meningococcal serogroup ACWY conjugate (MenACWY) vaccination in their national immunization schedules. DTaP-IPV-HB-PRP-T is a hexavalent vaccine that provides protection against six diseases. Read More

View Article
December 2018

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

Vaccine 2018 Dec 19;36(52):8039-8046. Epub 2018 Nov 19.

University of British Columbia Centre for Disease Control, Vancouver, BC, Canada.

Background: To address a high incidence of serogroup B invasive meningococcal disease (IMD-B) in the Saguenay-Lac-Saint-Jean region, Quebec, Canada, a mass vaccination campaign targeting nearly 60,000 individuals ≤20 years old was launched in May 2014. Because of the limited clinical experience with the four-component meningococcal B vaccine (4CMenB), active surveillance for adverse events following immunization (AEFI) was conducted. This paper reports 4CMenB AEFI surveillance findings. Read More

View Article
December 2018
1 Read

Experience implementing a university-based mass immunization program in response to a Meningococcal B outbreak.

Hum Vaccin Immunother 2018 Nov 21. Epub 2018 Nov 21.

d Medical Development, Scientific & Clinical Affairs , Pfizer Vaccines , Collegeville , PA , USA.

Neisseria meningitidis serogroup B (MenB) has caused several recent outbreaks of meningococcal disease on US college campuses. In January 2015, a case of MenB was reported at a university in Oregon, culminating in an outbreak with a total of 7 cases (including 1 fatality) identified over a 5-month period. In response to the outbreak, the university organized a mass immunization campaign with 4 "opt-in" immunization clinics. Read More

View Article
November 2018
2 Reads

Narrative review of methods and findings of recent studies on the carriage of meningococci and other Neisseria species in the African Meningitis Belt.

Trop Med Int Health 2018 Nov 21. Epub 2018 Nov 21.

Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.

Objective: To review the findings of studies of pharyngeal carriage of Neisseria meningitidis and related species conducted in the African meningitis belt since a previous review published in 2007.

Methods: PubMed and Web of Science were searched in July 2018 using the terms 'meningococcal OR Neisseria meningitidis OR lactamica AND carriage AND Africa', with the search limited to papers published on or after 1st January 2007. We conducted a narrative review of these publications. Read More

View Article
November 2018
6 Reads

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Expert Rev Vaccines 2018 Dec 5;17(12):1111-1121. Epub 2018 Dec 5.

d Vaccine Development Leader , Research and Development Centre , Rockville , MD , USA.

Introduction: Neisseria meningitidis serogroup B (MenB) is the most common cause of bacterial meningitis in many industrialized countries and occurs at any age. The highest incidence is in infants aged <1 year, followed by children and adolescents. Four-component MenB vaccine (4CMenB, Bexsero) is the only MenB vaccine authorized for use in all age-groups. Read More

View Article
December 2018
3 Reads

Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations.

Vaccine 2018 Nov 14. Epub 2018 Nov 14.

GSK srl, Via Fiorentina 1, 53100 Siena, Italy. Electronic address:

Pyrogen content is one of the critical quality attributes impacting the safety of a product, and there is an increasing need for assays that can reliably measure this attribute in vaccines. The Limulus amebocyte lysate (LAL) assay and the rabbit pyrogen test (RPT) are the canonical animal-based pyrogen tests currently used to release vaccines; however, there are several drawbacks associated with these tests when applied to Bexsero, intrinsically pyrogenic product, containing a meningococcal Outer Membrane Vesicle component. While the RPT, as applied to Bexsero at its given dilution, ensures safe vaccine, it is highly variable and prone to false positive results. Read More

View Article
November 2018
10 Reads

Development of a measure to assess vaccine confidence among men who have sex with men.

Expert Rev Vaccines 2018 Nov 15;17(11):1053-1061. Epub 2018 Nov 15.

b Rollins School of Public Health, Hubert Department of Global Health , Emory University , Atlanta , GA , USA.

Background: Recent serogroup C meningococcal disease outbreaks led to meningococcal vaccine recommendations for Southern California men who have sex with men (MSM). Assessment of vaccine confidence is critical to improving vaccine coverage in the context of disease outbreaks wherein immunization(s) are recommended.

Methods: We surveyed MSM using venue-based sampling and began development of the vaccine confidence index (VCI) with 30 survey items corresponding to trust- and safety-related perceptions. Read More

View Article
November 2018
5 Reads

Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals.

Front Immunol 2018 29;9:2500. Epub 2018 Oct 29.

Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, United States.

Since 2006, meningococcal serogroup C (MenC) conjugate (MCC) vaccines have been supplied by the Brazilian government for HIV-infected children under 13 years old. For measuring protection against MenC, the serum bactericidal antibody (SBA) assay is the method of choice. The characterization of T follicular helper cells (TFH) cells has been an area of intensive study because of their significance in multiple human diseases and in vaccinology. Read More

View Article
October 2018
4 Reads

Microevolution of Neisseria lactamica during nasopharyngeal colonisation induced by controlled human infection.

Nat Commun 2018 11 12;9(1):4753. Epub 2018 Nov 12.

Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO166YD, UK.

Neisseria lactamica is a harmless coloniser of the infant respiratory tract, and has a mutually-excluding relationship with the pathogen Neisseria meningitidis. Here we report controlled human infection with genomically-defined N. lactamica and subsequent bacterial microevolution during 26 weeks of colonisation. Read More

View Article
November 2018
3 Reads
10.742 Impact Factor

Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.

Vaccine 2018 Nov 7;36(50):7609-7617. Epub 2018 Nov 7.

GSK, Via Fiorentina, 1, 53100 Siena, Italy. Electronic address:

Background: Invasive meningococcal disease has its highest incidence in infants. Co-administration of serogroup B (4CMenB) and quadrivalent conjugate (MenACWY-CRM) vaccines could protect against 5 clinically-relevant meningococcal serogroups.

Methods: This phase 3b, open, multicenter study (NCT02106390), conducted in Mexico and Argentina, enrolled and randomized (1:1:1) 750 healthy infants to receive either 4CMenB co-administered with MenACWY-CRM (4CMenB/MenACWY group), 4CMenB (4CMenB group), or MenACWY-CRM alone (MenACWY group) at ages 3, 5, 7 and 13 months. Read More

View Article
November 2018
7 Reads

Impact of mandatory vaccination extension on infant vaccine coverages: Promising preliminary results.

Med Mal Infect 2018 Nov 5. Epub 2018 Nov 5.

Santé publique, épidémiologie et qualité des soins, EA 2694, université Lille, CHU Lille, 59000 Lille, France.

Objective: In France infant vaccines protecting against 11 diseases have changed from a recommended to a mandatory status for all children born on or after January 1, 2018. Using the Vaccinoscopie survey, we measured the impact of this new vaccination policy on vaccine coverage rates (VCRs) and on mothers' perception of vaccination.

Methods: Online survey with 1000 mothers of 0- to 11-month-old infants. Read More

View Article
November 2018
5 Reads

Unusual Neisseria species as a cause of infection in patients taking eculizumab.

J Infect 2018 Nov 6. Epub 2018 Nov 6.

Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Background: Non-meningococcal, non-gonococcal Neisseria spp. are typically commensal and rarely cause invasive disease. Eculizumab is a terminal complement inhibitor that increases susceptibility to meningococcal disease, but data on disease caused by typically-commensal Neisseria spp. Read More

View Article
November 2018
7 Reads

Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.

Pediatr Infect Dis J 2018 Nov 7. Epub 2018 Nov 7.

Sanofi Pasteur, USA.

Background: This study assessed a pediatric mixed hexavalent diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T)-pentavalent (DTaP-IPV//PRP-T)-hexavalent primary series schedule followed by a pentavalent booster.

Methods: Healthy infants (N=265) who had received a prior HB vaccination received a fully liquid, hexavalent vaccine (DTaP-IPV-HB-PRP-T) at 2 and 6 months of age and a reconstituted pentavalent vaccine (DTaP-IPV//PRP-T) at 4 months of age. Coadministered vaccines were pneumococcal vaccine (PCV13) at 2 and 4 months [and optionally at 6 months of age], rotavirus (RV) vaccine at 2-4-6 months, and meningococcal serogroup C vaccine at 2 months. Read More

View Article
November 2018
9 Reads